These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 1722792

  • 1. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [Abstract] [Full Text] [Related]

  • 2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS.
    N Engl J Med; 1992 Oct 22; 327(17):1185-91. PubMed ID: 1383816
    [Abstract] [Full Text] [Related]

  • 3. Finasteride for benign prostatic hyperplasia.
    Hasinski S, Miller JL, Rose LI.
    Am Fam Physician; 1992 Nov 22; 46(5):1511-4. PubMed ID: 1279965
    [Abstract] [Full Text] [Related]

  • 4. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O, Oishi K, Okada Y, Mizutani Y, Itokawa Y, Tomoyoshi T, Okada K, Komatz Y, Matsuda T, Takeuchi H.
    Hinyokika Kiyo; 1996 Apr 22; 42(4):323-31. PubMed ID: 8693970
    [Abstract] [Full Text] [Related]

  • 5. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF.
    Clin Pharm; 1993 Jan 22; 12(1):15-23. PubMed ID: 7679063
    [Abstract] [Full Text] [Related]

  • 6. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.
    N Engl J Med; 1998 Feb 26; 338(9):557-63. PubMed ID: 9475762
    [Abstract] [Full Text] [Related]

  • 7. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 26; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 8. Finasteride: the first 5 alpha-reductase inhibitor.
    Sudduth SL, Koronkowski MJ.
    Pharmacotherapy; 1993 Dec 26; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
    [Abstract] [Full Text] [Related]

  • 9. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.
    Prostate; 2009 Jun 01; 69(8):895-907. PubMed ID: 19267353
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 01; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 11. Thoughts on finasteride for benign prostatic hyperplasia.
    Anand A.
    Am Fam Physician; 1993 Sep 15; 48(4):582, 588. PubMed ID: 7691035
    [No Abstract] [Full Text] [Related]

  • 12. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 13. [5-alpha reductase inhibitor in prostatic adenoma?].
    Heinzl S.
    Med Monatsschr Pharm; 1990 Dec 10; 13(12):382-4. PubMed ID: 1705307
    [No Abstract] [Full Text] [Related]

  • 14. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
    Matzkin H, Chen J, Lewyshon O, Ayalon D, Braf Z.
    Horm Metab Res; 1992 Oct 10; 24(10):498-9. PubMed ID: 1281461
    [No Abstract] [Full Text] [Related]

  • 15. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS, Bryan J, Eardley I, Christmas TJ, Liu S, Holmes SA, Vale JA, Shanmuganathan K, Webb JA.
    Br J Urol; 1992 Jul 10; 70(1):65-72. PubMed ID: 1379107
    [Abstract] [Full Text] [Related]

  • 16. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 10; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 17. Finasteride for benign prostatic hypertrophy.
    Med Lett Drugs Ther; 1992 Sep 04; 34(878):83-4. PubMed ID: 1380630
    [No Abstract] [Full Text] [Related]

  • 18. New options for patients with benign prostatic hyperplasia.
    Ellenberger B.
    CMAJ; 1993 Feb 15; 148(4):543-7. PubMed ID: 7679313
    [No Abstract] [Full Text] [Related]

  • 19. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, Lundmo P, Pappas F, Round E, Shapiro D.
    Eur Urol; 1992 Feb 15; 22(4):271-7. PubMed ID: 1283370
    [Abstract] [Full Text] [Related]

  • 20. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 15; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.